Impact of a pharmacist-led oral chemotherapy-monitoring program in patients with metastatic castrate-resistant prostate cancer

With the introduction of oral chemotherapy, the paradigm for cancer treatment is shifting. Use of oral chemotherapy agents offers a non-invasive option for patients with metastatic castrate-resistant prostate cancer.

However, these medications are not without challenges including strict adherence for optimal effects, novel toxicity profiles, frequent lab parameter monitoring, high cost, and proper handling and disposal methods. Pharmacists are positioned to play a key role in providing patients with the education required to assure an optimal treatment course is carried out.

Two cohorts of patients receiving abiraterone, bicalutamide, or enzalutamide for metastatic castrate-resistant prostate cancer seen in our outpatient cancer center 21 months before and 24 months after the implementation of a pharmacist-led oral chemotherapy-monitoring program in December of 2012 were retrospectively compared. Patients were evaluated for number of interventions, adherence to lab parameter monitoring, and overall time on each therapy.

Of the 64 patients identified, 31 patients fulfilled inclusion criteria. A significant increase in the average number of interventions per patient (6. 9 vs. 2. 6; P = 0. 004) and adherence to lab parameter monitoring (10 vs. 3; P = 0. 04) in the post-program implementation cohort was found. However, no significant difference in overall time on therapy (10. 3 vs. 8. 1; P = 0. 341) between the two groups was observed.

These results suggest a potential opportunity exists to maximize oral chemotherapy treatment outcomes with the addition of a formalized monitoring program directed by an oncology pharmacist.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2015 Oct 22 [Epub ahead of print]

Jay M Patel, Lisa M Holle, Jessica M Clement, Thomas Bunz, Christopher Niemann, Kevin W Chamberlin

Smilow Cancer Hospital at Yale, New Haven, CT, USA. , UConn School of Pharmacy, John Dempsey Hospital/UConn Health, Storrs, CT, USA. UConn Health, Farmington, CT, USA. , New England Health Analytics, LLC, Granby, CT, USA. , John Dempsey Hospital/UConn Health, Farmington, CT, USA. , UConn School of Pharmacy, John Dempsey Hospital/UConn Health, Storrs, CT, USA.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe